iNtRON Biotechnology, Inc. (KOSDAQ:048530)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,060.00
-20.00 (-0.49%)
Apr 1, 2026, 3:30 PM KST
Market Cap124.46B -2.7%
Revenue (ttm)5.74B -10.6%
Net Income-8.96B
EPS-283.00
Shares Out30.65M
PE Ration/a
Forward PEn/a
Dividend100.00 (2.45%)
Ex-Dividend Daten/a
Volume354,342
Average Volume1,201,774
Open4,180.00
Previous Close4,080.00
Day's Range4,045.00 - 4,220.00
52-Week Range2,895.00 - 7,010.00
Beta0.30
RSI43.42
Earnings DateMar 27, 2026

About iNtRON Biotechnology

iNtRON Biotechnology, Inc. engages in the development of novel biopharmaceutical drugs in South Korea. It develops bacteriophage and endolysin based drugs through itLysin and IMPA platform. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 73
Stock Exchange KOSDAQ
Ticker Symbol 048530
Full Company Profile

Financial Performance

In 2025, iNtRON Biotechnology's revenue was 5.74 billion, a decrease of -10.56% compared to the previous year's 6.42 billion. Losses were -8.96 billion, 245.7% more than in 2024.

Financial Statements